Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Protein Engineering. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN109504645B details a high-efficiency biocatalytic route for 4-hydroxyisoleucine, offering superior yield and scalability for pharmaceutical intermediate manufacturing.
Patent CN113481175B discloses OYE2p mutants for stereoselective citral reduction. Discover cost-effective biocatalysis solutions for flavor and fragrance intermediates.
Patent CN115948360A details an imine reductase mutant achieving >99.5% conversion and 99.6% ee for nicotine analog intermediates, offering significant cost and supply chain advantages.
Patent CN109182298B details engineered lipase mutants for high-efficiency resolution of moxifloxacin intermediates, offering significant cost reduction and supply chain reliability.
Patent CN114667346B reveals a novel EanB mutant for efficient ergothioneine production. Discover cost-effective, scalable enzymatic synthesis solutions for global supply chains.
Patent CN120624386B reveals a high-pH stable alcohol dehydrogenase mutant for natural raspberry ketone. Enables cost reduction and scalable supply for flavor industries.
Patent CN115109759A reveals engineered carbonyl reductases achieving 600g/g S/C ratio. Discover cost-effective biocatalytic routes for chiral alcohol production.
Patent CN114196715A details a novel chemo-enzymatic method for pseudouridine using engineered glycosidase mutants, offering high conversion and simplified purification for mRNA vaccine supply chains.
Patent CN114507650A details a high-efficiency biocatalytic route for Clopidogrel intermediates, offering superior stereoselectivity and substrate tolerance for scalable API manufacturing.
Patent CN118480524B details mutant enzyme synthesis for chloramphenicol intermediates. Delivers high yield and green manufacturing advantages for reliable pharmaceutical intermediates supplier partnerships.
Patent CN110951706B details a high-activity R-omega-TA mutant for sitagliptin. Offers high ee value >99%, breaking technical monopolies and ensuring supply chain stability.
Novel (R)-ω-transaminase mutant enables high-conversion synthesis of Sitagliptin intermediates, offering cost-effective and scalable pharmaceutical manufacturing solutions.
Patent CN111411094B discloses a novel mutant enzyme achieving 95.4% conversion at high substrate concentrations, offering significant cost reduction in API manufacturing.
Patent CN110540975B reveals high-efficiency biocatalytic route for sitagliptin precursors, offering superior stereoselectivity and reduced environmental impact for pharma supply chains.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediate synthesis, offering superior conversion rates and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediates. Achieves 90% conversion with superior purity and reduced environmental impact for pharma supply chains.
Patent CN105734028A reveals high-efficiency epoxide hydrolase mutants for R-epichlorohydrin production, offering superior stability and supply chain reliability.
Patent CN105734028A reveals mutant epoxide hydrolase for high-purity R-epichlorohydrin. Enhances stability and activity for reliable pharmaceutical intermediate supply chains.
Patent CN109182298A reveals high-efficiency CALB mutants for chiral intermediate synthesis, offering cost reduction and scalable supply chain solutions for pharmaceutical manufacturing.
Patent CN105505904A reveals enhanced nitrilase mutant for high-purity (R)-mandelic acid production with improved selectivity and activity for reliable supply.